Checkpoint Therapeutics Inc 's ROA from the first quarter of 2025 to the first quarter of 2024 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Checkpoint Therapeutics Inc 's ROA in the first quarter of 2025?
Checkpoint Therapeutics Inc recorded a cumulative net loss of $-57 million during 12 months ending in the first quarter of 2025, resulting in a negative return on assets (ROA) of -430.66%.

However, within the Healthcare sector 986 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Mar 31 2025 quarter, so far to 4873, from total ROA ranking in the fourth quarter of 2024 at 5672.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Mar 31 2025) I. Quarter	(Dec 31 2024) IV. Quarter	(Sep 30 2024) III. Quarter	(Jun 30 2024) II. Quarter	(Mar 31 2024) I. Quarter
Y / Y Total Assets Change	185.29 %	38.92 %	133.5 %	-32 %	103.1 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-57	-56	-46	-42	-52
Return On Assets (TTM)	-430.66 %	-742.56 %	-659.07 %	-672.98 %	-749.84 %
CKPT's Total Ranking	# 4873	# 5672	# 5037	# 5099	# 5190
Total Assets (TTM) in million	34	7	5	6	12
Seq. Total Assets Change	357.29 %	44.26 %	-8.66 %	-52.65 %	122.67 %
Seq. Net Income Change	-	-	-	-	-

CKPT's 5 Years Annual ROA >> Back to CKPT Management Effectiveness >> Compare CKPT ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 483
Sector	# 987
Overall	# 4798

Return On Assets Statistics
High	Average	Low
-57.9 %	-253.63 %	-950.01 %
(Jun 30 2021)		(Dec 31 2023)

Financial Statements
Checkpoint Therapeutics Inc 's Assets	$ 34 million	CKPT's Balance sheet
Checkpoint Therapeutics Inc 's Income	$ -11 million	Quarterly CKPT's Income Statement
CKPT's Income by Division		See CKPT's Income by Division

Annual Return On Assets	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021	(Dec 31 2020) FY 2020
Y / Y Total Assets Change	38.92 %	-59.53 %	-76.15 %	30.83 %	57.96 %
Total Assets in million	7	5	13	56	43
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-56	-52	-63	-57	-23
Annual Return On Assets	-752.78 %	-964.06 %	-471.21 %	-101.69 %	-54.19 %

CKPT's 5 Years Annual ROA >> Back to CKPT Management Effectiveness >> Compare CKPT ROA to its Competitors

More Return On Assets Ratios
CKPT's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
CKPT's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for CKPT's Competitors
Subscribers only: Roa for Checkpoint Therapeutics Inc 's Suppliers
Subscribers only: Return On Assets for CKPT's Customers

You may also want to know
CKPT's Roi	CKPT's Inventory Turnover Ratio	CKPT's Growth Rates	CKPT's Dividend Comparisons
	CKPT's Profitability Ratios	CKPT's Asset Turnover Ratio	CKPT's Dividend Growth
CKPT's Roe	CKPT's Valuation Ratios	CKPT's Financial Strength Ratios	CKPT's Dividend Payout Ratio

Companies with similar Return On Assets at Mar 31 2025, within Healthcare Sector

ROA

Date modified: 2026-09-26T07:30:29+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.